Home Featured Page 153

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol...

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit...

Acid for Anxiety: Fast and Lasting Anxiolytic Effects of LSD

PT364 – Jamie Wheal – Burning Man, Psychedelic Maturity, and Radical...

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives...

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol...

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit...

Acid for Anxiety: Fast and Lasting Anxiolytic Effects of LSD

PT364 – Jamie Wheal – Burning Man, Psychedelic Maturity, and Radical...

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial...

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives...

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY